Supernus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Supernus Pharmaceuticals (SUPN).

Price Target Range — 7 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$62Upside to Avg. PT+52.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 9, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$63→$67
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Hold	$50→$55
Oct 29, 2025	B of A Securities	Pavan Patel	Initiate	Buy	$65
Oct 23, 2025	TD Cowen	Stacy Ku	PT Raise	Buy	$45→$60
Oct 9, 2025	Piper Sandler	David Amsellem	Upgrade	Neutral→Overweight	$40→$65
Sep 30, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$46→$63
Aug 29, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$36→$40
Aug 6, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$42→$46
Feb 26, 2025	Cantor Fitzgerald	Kristen Kluska	Maintained	Neutral	$36
Feb 19, 2025	Cantor Fitzgerald	Kristen Kluska	Downgrade	Overweight→Neutral	$57→$36
Sep 11, 2024	Piper Sandler	David Amsellem	Downgrade	Overweight→Neutral	$41→$36
Feb 28, 2024	Piper Sandler	David Amsellem	PT Cut	Overweight	$45→$41
Nov 9, 2023	Piper Sandler	David Amsellem	PT Raise	Overweight	$42→$43

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

Stifel analyst Annabel Samimy maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Hold and raises the price target from $50 to $55.

Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals (NASDAQ:SUPN) with a Buy rating and announces Price Target of $65.

Benzinga Newsdesk

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

Benzinga Insights

PRO
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Buy and raises the price target from $45 to $60.

Benzinga Newsdesk

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

Supernus Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Supernus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PRO
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

PRO
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

PRO
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

People Also Watch

People Also Watch

Supernus Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Supernus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PROStifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

PROB of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

PROTD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PRO
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

PRO
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

PRO
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60